Clinical trial
Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso; KOREA PLUS Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS).
NCT03918304 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso; KOREA PLUS Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS).
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 11, 2019
- Completion date
- October 27, 2024
- Enrollment
- 923 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.